"New Therapy Halts Tumor Growth by Targeting RAS Without Harming Healthy Cells"

Researchers at the Francis Crick Institute and Vividion Therapeutics have developed a new therapy that targets the RAS gene to halt tumor growth without harming healthy cells, marking a promising advance in cancer treatment.

• The novel therapy aims to prevent RAS gene interactions with key pathways, significantly impacting the treatment of various neoplasm types associated with cancer.
• This treatment is currently advancing into its first clinical trial, with hopes to provide effective options while minimizing side effects commonly seen with traditional therapies.
• The research identifies chemical compounds that inhibit the phosphoinositide 3-kinase pathway, crucial in tumor growth, indicating a potential shift in targeting mutation-driven cancers.